From Wikipedia, the free encyclopedia
Jump to: navigation, search
Perphenazine gamma-aminobutyrate.svg
CAS Number
PubChem CID
Chemical and physical data
Formula C25H33ClN4O2S
Molar mass 489.08 g·mol−1
3D model (JSmol)

BL-1020 (perphenazine gamma-aminobutyrate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia, it's an ester of GABA and perphenazine, and pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials.[1] In March 2013, it went into the II/III trial phase.[2] It has been introduced by BioLineRx, a biopharmaceutical development company.


  1. ^ Geffen, Y; Keefe, R; Rabinowitz, J; Anand, R; Davidson, M (September 2012). "Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study". The Journal of Clinical Psychiatry. 73 (9): e1168–74. doi:10.4088/jcp.12m07642. PMID 23059159. 
  2. ^ Biolinerx (Jan 7, 2013). "BioLineRx to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug during week of March 18, 2013". Biolinerx. Archived from the original on 2013-03-03.